Description

The ESMO World Congress on Gastrointestinal Cancer 2019 covers topics such as:

Bile Duct Cancer
- New agents/strategies on the horizon in bile duct cancer
- Molecular alterations in bile duct cancer
Cancer of the Pancreas
- Are we making progress in surgery of the pancreas?
- Genetics and molecular alterations in pancreatic cancer
- Improving the outcomes of patients with metastatic pancreatic cancer
- Adjuvant and neo-adjuvant treatment of pancreatic cancer in resectable pancreatic cancer
New Concepts in Clinical Trials
- Tumor agnostic trials and approaches
- Clinical interpretation and validity of clinical trials: When do they become practice-changing?
- Studying biosimilars: What is needed and what is the role of biosimilars?
- Studying value and health economics
Meet the Expert Presentations
- Advances in surgery of rectal cancer
- New endoscopic screening tools: NBI, chromoendoscopy - How do they help us?
- Progress in anal cancer
- Teaching on new evolutions in radiation oncology
- How to classify NET`s and NEC`s?
- Carcinoma of unknown origin
- ESMO Session: Focus on young medical oncologists
Relevant pathways in GI cancer: how relevant and how to approach them?
- The FGF pathway
- The HER-2 pathway
- NGS testing for all patients with GI cancers?
- Fusions in GI cancers
Esophageal and Gastric Cancers
- Barrett esophagus: Role of advanced endoscopy in the diagnosis and treatment
- Unraveling the molecular taxonomy in esophageal and gastric cancer
- Definitive CRT or neoadjuvant therapy followed by surgery in esophageal cancer
- Management of squamous cell cancer for the esophagus
- Surgery in oligometastastic gastric cancer?
- Locally advanced GE junction cancer: CRT or perioperative CT
- Metastatic gastric cancer: New targeted agents in metastatic gastric cancer
- Metastatic gastric cancer: Where are we with checkpoint inhibitors in gastric cancer?
Expert Highlights: What is New in This Disease in 2019?
- What is new in GIST?
- What is new in NET?
- What is new in bile duct cancer?
- What is new in anal cancer?
- Genetic testing for familial and hereditary colorectal cancer
- Prevention and Screening of Colon Cancer
- Will chemoprevention become a reality?
- Screening for colon cancer: What has been achieved in 2019 & new prospects?
Hepatocellular Carcinoma
- Locoregional treatment for HCC
- How to integrate new agents in HCC?
- Multidisciplinary tumor board on HCC
Molecular Biology in CRC
- Current status and perspectives on liquid biopsies in GI cancer
- How to approach the patient with a BRAF mutant tumor?
- Practical implications of the molecular and immunologic classifications in CRC
- Is circulating DNA relevant in stage II colon cancer?
- Is broad NGS testing useful in my patients with metastatic colorectal cancer?
Multimodality Therapy for Rectal Cancer
- Rectal cancer after neoadjuvant therapy with complete clinical response: Surgery or watchful waiting
- Imaging in rectal cancer
- Adjuvant chemotherapy in rectal cancer or introduce more neo-adjuvant chemotherapy
- New evolutions and ideas in surgery
- The strategy in synchronous liver metastases of rectal cancer
Multidisciplinary Tumor Boards
- The challenging patient with HCC
- Molecular and hereditary tumor board
- The challenging patient with colorectal cancer
Key Note Lectures
- Novel immune oncology mechanisms and approaches in GI cancers: where are we?
- The microbiome in GI cancers
- Should DPD deficiency be searched before starting 5FU?
- What to do with a malignant colon polyp?
- How to look for minimal residual disease?
- Relevant drug interactions in GI Oncology
Colorectal Cancer
- Chemorefractory colorectal cancer
- Updates on treatment algorithms in metastatic CRC in 2019
- Can we refine the selection for adjuvant treatment in stage II colon cancer?
- Can we refine the selection for adjuvant treatment in stage III colon cancer?
Immune Mechanisms and Immune Therapy in GI Cancer
- Biomarkers for check-point inhibitors in GI cancer
- How to improve the results with IO agents in MSI GI cancer?
- Are we making progress with IO in pancreatic cancer?
- How can we increase the immunogenicity in MSS CRC?
- The link between the immune microenvironement and outcome in colorectal cancer
Clinical Updates
- Liver resection of liver metastases
- When and how to select for debulking and HIPEC in peritoneal carcinomatosis?